DocumentsDate added
Original article:
Xiaoyong Jin1,Zheng Liu2,Baojian Guo1,Gaoxiao Zhang2,Zaijun Zhang2,Lipeng Xu2,Yuqiang Wang2,Yewei Sun2*
1 Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, Jinan University College of Pharmacy,Guangzhou, 510632, China
2 Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, 510632, China
Address reprint requests to
*Yewei Sun, Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, Jinan University College of Pharmacy,Guangzhou, 510632, China
Article citation: Jin X, Liu Z, Guo B,Zhang G, Zhang Z, Xu L, Wang Y, Sun Y. A promising dual-functional neuroprotective derivative of memantine. J Pharm Biomed Sci 2016;06(06):392–398.Available at www.jpbms.info
ABSTRACT
Background Memantine, an open-channel, uncompetitive blocker of NMDA receptors, is a major treatment for moderate-to-severe Alzheimer’s disease. The NMDA receptor activity can also be inhibited allosterically by S-nitrosylation of Cys residues, a redox-mediated chemical reaction.
Aim To enhance the inhibitory effect of memantine on NMDA receptors and its neuroprotective effect. Settings and Design In this study, we designed and synthesized a memantine nitrate compound (MN-2, also known as YQW-035), with the potential for both allosteric and direct uncompetitive blockade. Then, the protective effects of MN-2 were evaluated both in vitro and in vivo.
Results and Conclusions Biological evaluations demonstrated that MN-2 showed a stronger protective effect in cultured neuronal cells and in a rat transient stroke model compared with memantine. The mechanism underlying the action of MN-2 may be attributed to its dual inhibition of NMDA receptors. These results suggested MN-2 has promising potential for treatment of various neurological disorders characterized by overstimulation of NMDA receptors.
KEYWORDS memantine nitrate, neurological disorder, NMDA receptor, S-nitrosylation
REFERENCES
1.Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr. 2000;130:1007–1015.
2.Campos F, Perez-Mato M, Agulla J, Blanco M, Barral D, Almeida A, et al. Glutamate excitoxicity is the key molecular mechanism which is influenced by body temperature during the acute phase of brain stroke. PLoS One. 2012;7(8):e44191.
3.Nguyen D, Alavi MV, Kim KY, Kang T, Scott RT, Noh YH, et al. A new vicious cycle involving glutamate excitotoxicity, oxidative stress and mitochondrial dynamics. Cell Death Dis. 2011;2:e240.
4.Hazell AS. Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. Neurochem Int. 2007;50:941–953.
5.Sattler R, Tymianski M. Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. Mol Neurobiol.2001;24:107–129.
6.Szydlowska K, Tymianski M. Calcium, ischemia and excitotoxicity.Cell Calcium. 2010;47:122–129.
7.Arundine M, Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium.2003;34:325–337.
8.Skaper SD, Facci L, Strijbos PJ. Neuronal protein kinase signaling cascades and excitotoxic cell death. Ann N Y Acad Sci. 2001;939:11–22.
9.Chen H, Lipton SA. Mechanism of memantine block of NMDAactivated channels in rat retinal ganglion cells: uncompetitive antagonism. J Physiol. 1997;499:27–46.
10.Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig NH, Rogers JT, et al. N-Methyl D-Aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s disease, vascular dementia and Parkinson’s disease. Curr Alzheimer Res. 2012;9:746–758.
11.Chen H, Wang Y, Rayudu P, Edgecomb P, Neill J, Segal M, et al.Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience. 1998;86:1121–1132.
12.Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology. 2007;53: 699–723.
13.Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA. 1991;88:6368–6371.
14.Choi YB, Tenneti L, Le DA, Ortiz J, Bai G, Chen HV, et al. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat Neurosci. 2000;3:15–21.
15.Zurakowski D, Vorwerk CK, Gorla M, Kanellopoulos AJ, Chaturvedi N, Grosskreutz CL, et al. Nitrate therapy may retard glaucomatous optic neuropathy, perhaps through modulation of glutamate receptors. Vision Res. 1998;38:1489–1494.
16.Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HSV, Sucher NJ, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature. 1993;364:626–632.
17.Stroke TAIRS. Recommendations for standards regarding preclinical neuroprotective and restorative drug development.Stroke. 1999;30:2752.
18.Chen CJ, Liao SL, Chen WY, Hong JS, Kuo JS. Cerebral ischemia/reperfusion injury in rat brain: effects of naloxone. Neuroreport.2001;12:1245–1249.
19.Woodruff TM, Thundyil J, Tang SC, Sobey CG, Taylor SM, Arumugam TV. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol Neurodegener.2011;6:11.
20.Jiang Q, Jiang Y, Wang J, Qin J, Wu X. An improved method for primary culture of rat cortical neuron and cell identification.Beijing Da Xue Xue Bao. 2009;41:212–216.
21.Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84–91.
22.Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol. 2006;6:61–67.
23.Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C,Sharp FR. A semiautomated method for measuring braininfarct volume. J Cereb Blood Flow Metab. 1990;10:290–293.
24.Maier CM, Cheng ML, Lee JE, Yenari MA, Steinberg GK. Optimal depth and duration of mild hypothermia in a focal model of transient cerebral ischemia effects on neurologic outcome, infarct size, apoptosis and inflammation. Stroke. 1998;29:2171–2180.
ORIGINAL ARTICLE
Min Yang,S-Shan Zhou,Y-Zhen Zhang,Guo-hua Cheng*
School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, China, P.C. 510632
Address reprint requests to
*Guo-hua Cheng, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, China, P.C. 510632
Article citation: Yang M, Zhou SS, Zhang YZ, Cheng GH. A systematic review for the contraceptive efficacy and safety of compound left acetylene progesterone tablets. J Pharm Biomed Sci 2016;06(06):381–386. Available at www.jpbms.info
ABSTRACT
Background and Objectives There is limited information on the efficacy and safety of compound left acetylene progesterone tablets (LNG/EE 100/20 μg) in contraception. To evaluate the efficacy and safety of LNG/EE 100/20 μg for contraception.
Method We searched the medical databases including Pubmed, Web of science, EMbase and Cochrane library through computer; extracted and evaluated the data then performed the meta-analysis by using Review Manager 5.3 software.
Result A total of seven randomised controlled trials including 1786 subjects were recruited for meta-analysis. Compared with other compound oral contraceptives, LNG/EE 100/20 μg showed no significant differences in contraception efficacy [OR = 1.08, 95% CI (0.29, 4.04), P = 0.91] and safety [OR = 0.99, 95% CI (0.81, 1.21), P = 0.92]; however, it is better than the other compound oral contraceptives on cycle control efficacy of short cycle [OR = 1.75, 95% CI (1.28, 2.38), P = 0.0004].
Conclusion LNG/EE 100/20 μg were better than the other compound oral contraceptives on cycle control of short cycle, and showed no significant differences in the efficacy and safety.
KEYWORDS compound left acetylene progesterone tablets; contraception; efficacy; safety; meta-analysis
REFERENCES
1.Huang ZR, Wu SC. Development and application of combined oral contraceptives. J Int Reprod Health Fam Plan. 2009;28(3):139–144.
2.Cheng HL, Gao ES. Research report for oral contraceptives and contraceptives. J Reprod Contracept. 2006;26(1):31–46.
3.Mishell DR Jr. Oral contraception: past, present, and future perspectives.Int J Fertil. 1991;36(1):7–18.
4.Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol. 1992;21(1):48–52.
5.Sartoretto JN, Ortega-Recio JC. Clinical evaluation of a low dosage estrogen-progesterone association (100 μg of d-norgestrel and 20 μg of ethinyl estradiol). Rev Bras Clin Ther. 1974;3(1):399–404.
6.Hartling L, Ospina M, Liang YY, Dryden DM, Hooton N, Seida JK, et al. Risk of bias versus quality assessment of randomised controlled trials: cross sectional study. BMJ. 2009;339:b4012.
7.Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
8.Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193–206.
9.Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
10.Reisman H, Martin D, Michael J. A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 μg levonorgestrel with 20 μg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol. Am J Obstet Gynecol. 1999;181:45–52.
11.Endrikat J, Hite R, Bannemerschult R, Gerlinger C, Schmidt W. Multilateral, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 μg ethinylestradiol/100 μg levonorgestrel and 20 μg ethinylestradiol/500 μg norethisterone. Contraception.2001;64:3–10.
12.Jespersen J, Endrikat J, Dűsterberg B, Schmidt W, Gerlinger C, Wessel J, et al. A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 μg of ethinylestradiol and 100 μg of levonorgestrel with 30 μg of ethinylestradiol and 100 μg of levonorgestrel. Contraception.2005;72:98–104.
13.Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception. 2006;74:220–223.
14.Seidman L, Kroll R, Howard B, Ricciotti N, Hsieh J, Weiss H. Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial. Contraception. 2015;91:495–502.
15.DelConte A, Loffer F, Grubb GS. Cycle control with oral contraceptivescontaining 20 μg of ethinyl estradiol: a multicenter, randomized comparison of levonorgestrel/ethinylestradiol (100μg/20 μg) and norethindrone/ethinylestradiol (1000 μg/20 μg).Contraception. 1999;59:187–193.
16.Endrikat J, Klipping C, Cronin M, Gerlinger C, Ruebig A, Schmidt W, et al. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception. 2002;65:215–221.
17.Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low-and lower-dose oral contraceptives: a randomized trial of 20 μg and 35 μg estrogen preparations. Contraception. 1999;60:321–329.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Research article
Wen Hou,Ping-Hua Sun,Zhi-Zhong Geng,Hong-Gui Xu,Jing Lin,Wei-Min Chen*
College of Pharmacy, Jinan University, Guangzhou 510632, China
Address reprint requests to:
*Wei-Min Chen, Department of Medicinal Chemistry, College of Pharmacy, Jinan University, Guangzhou 510632, China
Article citation: Hou W, Sun PH, Geng ZZ, Xu HG, Lin J, Chen WM. Design, synthesis and antibacterial assay of pinosylvin acid derivatives. J Pharm Biomed Sci 2016;06(06):369–373. Available at www.jpbms.info
Abstract:
In this study, a series of Pinosylvin acid (PA) derivatives 3a-3g and 4e were designed and synthesized from 2-acetoxy-6-((diethoxyphosphoryl)methyl)-4-methoxybenzoate and aromatic aldehyde. All structures of target PA derivatives 3a-3g and 4e were characterized by 1H-NMR and MS. Corresponding in vitro antibacterial activities were evaluated by broth dilution method. Among 3a-3g, derivative 3e exhibited potent antibacterial activity against Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis and MRSA, with a value of MIC against MRSA reaching 16 g/mL. Another type of target compound, 4e, was optimized from 3e by structural modification. Its corresponding value of MIC against MRSA was up to 0.5•g/mL, which was 32-fold stronger than that of norfloxacin. Meanwhile, cytotoxic assay revealed 4e possessed a good selective index between bacterial and normal cells, indicating the potential apply of 4e as an antibacterial agent in clinical application. Based on this preliminary achievement, further investigations including in vivo antibacterial effect and in vivo toxicity tests are still in process.
KEYWORDS antibacterial activity, MRSA, pinosylvin acid derivatives, synthesis.
REFERENCES
1.Coates A, Hu YM, Bax R, Page C. The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov.2002;1(12):895–910.
2.Tan CM, Therien AG, Lu J, Lee SH, Caron A, Gill CJ, et al. Restoring methicillin-resistant Staphylococcus aureus susceptibility to beta-lactam antibiotics. Sci Transl Med. 2012;4(126):126–135.
3.Zhao J, Fu Y, Luo M, Zu Y, Wang W, Zhao C, et al. Endophytic fungi from pigeon pea [Cajanus cajan (L.) Millsp.] produce antioxidant Cajaninstilbene acid. J Agr Food Chem. 2012;60(17):4314−4319.
4.Zhang W, Sviripa V, Kril LM, Chen X, Yu T, Shi J, et al.Fluorinated N,N-Dialkylaminostilbenes for WNT pathway inhibition and colon cancer repression. J Med Chem. 2011;54(5):1288–1297.
5.Flaherty DP, Kiyota T, Dong Y, Ikezu T, Vennerstrom JL. Phenolic bis-styrylbenzenes as β-amyloid binding ligands and free radical scavengers. J Med Chem. 2010;53(22):7992–7999.
6.Kima YS, Shin DH. Volatile components and antibacterial effects of pine needle (Pinus densiflora S. and Z.) extracts. Food Microbiol. 2005;22(1):37–45.
7.Cooksey CJ, Dahiya JS, Garratt PJ, Strange RN. Two novel stilbene-2-carboxylic acid phytoalexins from Cajanus cajan.Phytochemistry. 1980;21(12):2935–2938.
8.Kong Y, Fu YJ, Zu YG, Chang FR, Chen YH, Liu XL, et al. Cajanuslactone, a new coumarin with anti-bacterial activity from pigeon pea [Cajanus cajan (L.) Millsp.] leaves. Food Chem. 2010; 121(4):1150–1155.
9.Ji XY, Xue ST, Zheng GH, Han Y-X, Liu Z-Y, Jiang J-D, et al. Total synthesis of cajanine and its antiproliferative activity against human hepatoma cells. Acta Pharma Sin B. 2011;1(2):93–99.
10.Maryanoff BE, Reitz AB. The Wittig olefination reaction and modifications involving phosphoryl-stabilized carbanions. Stereochemistry, mechanism, and selected synthetic aspects. Chem Rev. 1989;89(4):863–927.
11.Song YY, He HG, Li Y, Deng Y. A facile total synthesis of amorfrutin A. Tetrahedron Lett. 2013;54(21):2658–2660.
12.Barron D, Ibrahim RK. Isoprenylated flavonoids-a survey. Phytochemistry. 1996;43(5):921–982.
13.Jordão AK, Novais J, Leal B, Escobar AC, dos Santos HM Jr, Castro HC et al. Synthesis using microwave irradiation and antibacterial evaluation of new N,O-acetals and N,S-acetals derived from 2-amino-1,4-naphthoquinones. Eur J Med Chem. 2013;63:196–201.
14.Suresh N, Nagesh HN, Renuka J, Rajput V, Sharma R, Khan IA,et al. Synthesis and evaluation of 1-cyclopropyl-6-fluoro-1,4- dihydro-4-oxo-7-(4-(2-(4-substitutedpiperazin-1-yl)acetyl)piperazin-1-yl)quinoline-3-carboxylic acid derivatives as anti- tubercular and antibacterial agents. Eur J Med Chem. 2014;71:324–332.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The authors have no financial conflicts of interest.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
MinSong1,Mei-HuaGao1,2,Wei-Huan Huang1,Man-Mei Li1,Hua Li2,Yao-Lan Li1,Xiao-Qi Zhang1*,Wen-Cai Ye1
1 Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou 510632, China
2 Guangdong Institute for Food and Drug Control, Guangzhou 510180, China
Address reprint requests to:
*Xiao-Qi Zhang,
College of Pharmacy, Jinan University, No. 601 West Huangpu Avenue, Guangzhou 510632, China
Article citation: MinSong, Mei-HuaGao, Huang WH, Li MM, Li H, Li YL, et al.Flavonoids from the seeds of Hovenia acerba and their in vitro antiviral activity. J Pharm Biomed Sci 2016;06(06):401–409.Available at www.jpbms.info
ABSTRACT
A new flavonoid, 6″′-acetyl-spinosin (12), together with 14 known flavonoids, were isolated from Hovenia acerba. Their structures were elucidated by extensive spectroscopic methods. The rotamers of four flavonoid C-glycosides 12–15 was investigated for the first time. All the flavonoids were evaluated for their anti-RSV activity by cytopathic effect (CPE) reduction assay. As a result, five flavonoids, 3, 7, 10, 13, and 14, displayed better antiviral effect against three RSV strains. Plaque reduction assay demonstrated that compound 13 mainly inhibited the intracellular replication of RSV. HPLC analysis indicated that the active compounds 3, 7, and 13 had higher contents in the seeds.
KEYWORDS Hovenia acerba, Rhamnaceae, flavonoids, antiviral activity, RSV
REFERENCES
1.Kott V, Barbini L, Cruanes M, Munoz JD, Vivot E, Cruanes, et al. Antiviral activity in Argentine medicinal plants. J Ethnopharmacol.1999;64(1):79–84.
2.Antonelli G, Turriziani O. Antiviral therapy: old and current issues. Int J Antimicrob Agents. 2010;40(2):95–102.
3.Glatthaar Saalmüller B, Rauchhaus U, Rode S, Haunschild J,Saalmüller A. Antiviral activity in vitro of two preparations of the herbal medicinal product sinupret against viruses causing respiratory infections. Phytomedicine. 2011;19(1):1–7.
4.Hyun TK, Eom SH, Yu CY, Roitsch T. Hovenia dulcis – an Asian traditional herb. Planta Med. 2010;76(10):943–949.
5.Chen YL, Carsten S. Rhamnaceae. In: Raven PH, Zhang LB,AI-Shehbaz IA, Turland NJ, Zhu GH, editors. Flora of China. Beijing: Science Press. 2008; p. 117–119.
6.Zhang XQ, Xu FF, Wang L, Huang MY, LiuZ, Zhang DM, et al. Two pairs of new diastereoisomeric flavonolignans from the seeds of Hovenia acerba. Phytochem Lett. 2012;5(2):292–296.
7.Kim DH, Sung NY, Kim JS, Kim JH, Hwang YJ, Lee JW.Alcohol metabolizing and antioxidant activities of complex herbal extracts from medicinal plants. Food Sci Biotechnol.2011;20(5):1337–1345.
8.Xu BJ, Deng YQ, Sung CK. Advances in studies on bioactivity of Hovenia dulcis. Agric Chem Bio. 2004;47(1):1–5.
9.Xu FF, Fan CL, Wang L, Wang GC, Zhang XQ, Ye WC. Chemical constituents from the seeds of Hovenia acerba. J Jinan Univ Nat Sci Med (China). 2011;32(3):304–306.
10.Liang QL, Ding LS. Chemical constituents from the leaves of Hovenia acerba. Chin. Tradit Herbal Drugs (China). 1996;27(7):581–583.
11.Ding LS, Liang QL, Teng YF. Flavone constituents from the seeds of Hovenia acerba. J Pharmaceutical. 1997;32(3):600–602.
12.Yoshikawa M, Murakami T, Ueda T, Yoshizumi S, Ninomiya K,Murakami N, et al. Bioactive constituents of Chinese natural medicines. III. Absolute stereo structures of new dihydroflavonols, hovenitins I, II, and III, isolated from hoveniae semen seufructus, the seed and fruit of Hovenia dulcis THUNB. (Rhamnaceae): inhibitory effect on alcohol-induced muscular relaxation and hepatoprotective activity. Yakugaku Zasshi. 1997;117:108–118.
13.Takahashi H, Li S, Harigaya Y, Onda M. Heterocycles. X XII.Stereoselective synthesis of (+)-aromadendrin trimethyl ether and its enantiomer, and their reduction. Chem Pharm Bull.1988;36(5):1877–1881.
14.Jeon SH, Chun W, Choi YJ, Kwon YS. Cytotoxic constituents from the bark of Salix hulteni. Arch Pharm Res. 2008;31(8):978–982.
15.Huang DW, Chung CP, Kuo YH, Lin YL, Chiang W. Identification of compounds in adlay (Coixlachryma-jobi L. var. ma-yuen Stapf ) seed hull extracts that inhibit lipopolysaccharide-induced inflammation in RAW 264.7 macrophages. J Agric Food Chem. 2009;57(22):10651–10657.
16.Foo LY, Newman R, Waghorn G, McNabb WC, Ulyatt MJ. Proanthocyanidins from Lotus corniculatus. Phytochemistry. 1996;41(2):617–624.
17.Cheng G, Bai YJ, Zhao YY, Tao J, Liu Y, Tu GZ, et al. Flavonoids from Ziziphusjujuba Mill var. spinosa. Tetrahedron. 2000;56(45):8915–8920.
18.Woo WS, Kang SS, Wagner H, Seligmann O, Chari VM. Acylated flavone-C-glycosides from the seeds of Zizyphus jujube.Phytochemistry. 1980;19(12):2791–2793.
19.Ooi LS, Wang H, He Z, Ooi VE. Antiviral activities of purified compounds from Youngia japonica (L). DC (Asteraceae, Compositae). J Ethnopharmacol. 2006;106(2):187–191.
20.Li Y, Ooi LSM, Wang H, But PP, Ooi VE. Antiviral activities of medicinal herbs traditionally used in southern mainland China. Phytother Res. 2004;18(9):718–722.
21.Li YL, Leung KT, Yao FH, Ooi LSM, Ooi VEC. Antiviral flavans from the leaves of Pithecellobium clypearia. J Nat Prod. 2006;69(5):833–835.
22.Ho WS, Xue JY, Sun SS, Ooi VE, Li YL. Antiviral activity of daphnoretin isolated from Wikstroemia indica. Phytother Res. 2010;24(5):657–661.
23.Lewis KC, Maxwell AR, McLean S, Reynolds WF, Enriquez RG.Room-temperature (1H, 13C) and variable-temperature (1H) NMR studies on spinosin. Magn Reson Chem. 2000;38(9):771–774.
24.Li YL, Li KM, Su MX, Leung KT, Chen YW, Zhang YW. Studies on antiviral constituents in stems and leaves of Pithecellibium clypearia. China J Chin Mater Med (China). 2006;31(5):397–400.
25.Shen XR, Zhang DZ. Research advances in plants of Genus Hovenia. Shizhen Guoyi Guoyao (China). 2007;18(6):1351–1355.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: This work was supported by grants from the National Natural Science Foundation (No. 81373935), the Science and Technology Planning Project of Guangdong Province (No. 2013A022100028), and the Administration of Traditional Chinese Medicine of Guangdong Province (No. 20131139).
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
REVIEW ARTICLE
Sarika Srivastava1,Priya Ranjan Kumar2*,Santosh Kumar Mishra2
1 Assistant Professor, IMS Ghaziabad (University Courses Campus), NH24, Adhyatmik Nagar, Ghaziabad, UP, India
2 Assistant Professor, IMS Engineering College, NH24, Adhyatmik Nagar, Ghaziabad, UP, India
Address reprint requests to
*Priya Ranjan Kumar, Assistant Professor, IMS Engineering College, NH24, Adhyatmik Nagar, Ghaziabad, UP, India
Article citation: Srivastava S, Kumar PR, Mishra SK. Identification of metabolites through GC/LC–MS processed data using different reference libraries and their comparison. J Pharm Biomed Sci 2016;06(06):363–368. Available at www.jpbms.info
ABSTRACT
Much significant advancement has been reported in the last few years in the field of metabolomics studies. The high-end computer applications are already contributing to the research and analysis in the field of life sciences. There are many hardware and softwares available, which can be used with various biomolecular separation and analysis instruments like chromatography, mass spectroscopy (MS), NMR, etc. The metabolite identification is the crucial part of the metabolomics study. The biosample collected from any resource need to be analysed from GC/LC–MS or NMR-type instrumentation to precisely identify the compounds present in the sample qualitatively and quantitatively. There are many tools and databases already available which can be used for the pre-processing, processing and analysis of raw data generated from these instruments. Various reference libraries are also available, which can be used for the identification of metabolites present in the sample after the processing of raw data. In this study, we have reviewed and compared different libraries and tools available for the metabolite identification from GC/ LC–MS data.
KEYWORDS metabolomics, reference libraries, GC–MS, LC–MS, metabolite profiling
REFERENCES
1.Brown M, Wedge DC, Goodacre R, Kell DB, Baker PN, Kenny LC, et al. Automated workflows for accurate mass-based putative metabolite identification in LC/MS-derived metabolomic datasets. Bioinformatics. 2011;27:1108–1112.
2.Aggio RB, Mayor A, Reade S, Probert CS, Ruggiero K. Identifying and quantifying metabolites by scoring peaks of GC–MS data. BMC Bioinformatics. 2014;15:374.
3.Smith CA, Want EJ, O’Maille G, Abagyan R, Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem. 2006;78:779–787.
4.Stein SE. An integrated method for spectrum extraction and compound identification from gas chromatography/mass spectrometry data. J Am Soc Mass Spectrom. 1999;10:770–781.
5.Qualitative methods of GC/MS analysis: library search. Retrieved from: http://www.shimadzu.com/an/gcms/support/fundamentals/ library.html
6.Kopka J, Schauer N, Krueger S, Birkemeyer C, Usadel B, Bergmüller E, et al. GMD@CSB.DB: the Golm metabolome database. Bioinformatics.2005;21:1635–1638.
7.Kind T, Wohlgemuth G, Lee do Y, Lu Y, Palazoglu M, Shahbaz S,et al. FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. Anal Chem. 2009;81:10038–10048.
8.Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B, et al.HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 2009;37:603–610.
9.Warwick B, Dunn WB, Erban A, Weber RJM, Creek DJ, Brown M, et al. Mass appeal: metabolite identification in mass spectrometry-focused untargeted metabolomics. Metabolomics.2013;9:44–66.
10.Tiller PR, Yu S, Castro-Perez J, Fillgrove KL, Baillie TA. Highthroughput, accurate mass liquid chromatography/tandem mass spectrometry on a quadrupole time‐of‐flight system as a ‘first‐line’ approach for metabolite identification studies. Rapid Commun Mass Spectrom. 2008;22:1053–1061.
11.Schauer N, Steinhauser D, Strelkov S, Schomburg D, Allison G, Moritz T, et al. GC–MS libraries for the rapid identification of metabolites in complex biological samples. FEBS Lett. 2005;579:1332–1337.
12.Zhu ZJ, Schultz AW, Wang J, Johnson CH, Yannone SM, Patti GJ,et al. Liquid chromatography quadrupole time-of-flight characterization of metabolites guided by the METLIN database. Nat Protoc. 2013;8:451–460.
13.Smith CA, O’Maille G, Want EJ, Qin C, Trauger SA, Brandon TR,et al. METLIN: a metabolite mass spectral database. Ther Drug Monit. 2005;27:747–751.
14.Tautenhahn R, Cho K, Uritboonthai W, Zhu Z, Patti GJ, Siuzdak G. An accelerated workflow for untargeted metabolomics using the METLIN database. Nat Biotechnol. 2012;30:826–828.
15.Giarrocco V, Quimby B, Klee M. Retention time locking: concepts and applications. Little falls: Agilent Technologies Publication. 1997.
16.Agilent G1676AA Fiehn GC/MS metabolomics RTL library, user guide. Retrieved from: http://www.agilent.com/cs/library/usermanuals/Public/G1676-90001_Fiehn.pdf.
17.NIST 14 mass spectral & search software. Retrieved from: http://www.sisweb.com/software/ms/nist.htm.
18.NIST/EPA/NIH mass spectral library (NIST 14) and NIST mass spectral search program (Version 2.2), user guide. Retrieved from: http://www.nist.gov/srd/upload/NIST1aVer22Man.pdf.
19.Automated mass spectrometry deconvolution and identification system (AMDIS), user guide. Retrieved from: http://chemdata.nist.gov/mass-spc/amdis/docs/amdis.pdf.
20.Tautenhahn R, Patti GJ, Rinehart D, Siuzdak G. XCMS online: a web-based platform to process untargeted metabolomic data.Anal Chem. 2012;84:5035–5039.
21.Horai H, Arita M, Kanaya S, Nihei Y, Ikeda T, Suwa K, et al.MassBank: a public repository for sharing mass spectral data for life sciences. J Mass Spectrom. 2010;45:703–714.
22.Madison-Qingdao Metabolomics Consortium Database. Retrieved from: http://mmcd.nmrfam.wisc.edu/main.html.
23.Cui Q, Lewis IA, Hegeman AD, Anderson ME, Schulte JLCF,Westler WM, et al. Metabolite identification via the Madison Metabolomics Consortium Database. Nat Biotechnol. 2008;26:162–164.
24.Creek DJ, Jankevics A, Burgess KE, Breitling R, Barrett MP. IDEOM: an excel interface for analysis of LC–MS-based metabolomics data. Bioinformatics. 2012;28:1048–1049.
25.Wang J, Peake DA, Mistrik R, Huang Y. A platform to identify endogenous metabolites using a novel high performance Orbitrap MS and the mzCloud Library. Blood. 2013;4:2–8.
26.Sheldon MT, Mistrik R, Croley TR. Determination of ion structures in structurally related compounds using precursor ion fingerprinting. J Am Soc Mass Spectrom. 2009;20:370–376.
27.Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27–30.
28.Brown M, Dunn WB, Dobson P, Patel Y, Winder CL, Francis-McIntyre S, et al. Mass spectrometry tools and metabolite-specific databases for molecular identification in metabolomics Analyst. 2009;134:1322–1332.
29.Brown M, Wedge DC, Goodacre R, Kell DB, Baker PN, Kenny LC,et al. Automated workflows for accurate mass-based putative metabolite identification in LC/MS-derived metabolomic datasets. Bioinformatics. 2011;27:1108–1112.
30.Kuhl C, Tautenhahn R, Böttcher C, Larson TR, Neumann S. CAMERA:an integrated strategy for compound spectra extraction and annotation of liquid chromatography/mass spectrometry data sets. Anal Chem. 2011;84:283–289.
31.Kessler N, Walter F, Persicke M, Albaum SP, Kalinowski J,Goesmann A, et al. ALLocator: an interactive web platform for the analysis of metabolomic LC–ESI–MS datasets, enabling semi-automated, user-revised compound annotation and mass isotopomer ratio analysis. PLoS One. 2014;9:e113909.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Sources of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.